Skip to Content
Merck
  • Lithium carbonate in the treatment of movement disorders. A critical review.

Lithium carbonate in the treatment of movement disorders. A critical review.

International pharmacopsychiatry (1980-01-01)
R Yassa, J Ananth
ABSTRACT

In this paper, the efficacy of lithium therapy in the treatment of tardive dyskinesia is reviewed. It is noted that most of the published papers on this topic are anecdotal and single case reports with contradictory results. The well-designed studies indicate that lithium is useful in certain tardive dyskinesia patients and that the red blood cell lithium level may be related to the therapeutic response. Therefore, on the basis of the available information, we conclude that routine clinical application of lithium in the treatment of tardive dyskinesia is not warranted. However, further evaluation of lithium in the treatment of tardive dyskinesia and identification of the responders are extremely useful. In addition, as suggested by animal studies, the prophylactic value of this agent against tardive dyskinesia needs exploration.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lithium carbonate, puriss. p.a., ACS reagent, reagent (for microscopy), ≥99.0% (T)
Sigma-Aldrich
Lithium carbonate, ACS reagent, ≥99.0%
Sigma-Aldrich
Lithium carbonate, 99.997% trace metals basis
Sigma-Aldrich
Lithium carbonate, 99.999% trace metals basis